Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA-597 (miR-597) is a small, non-coding RNA molecule classified as a microRNA, involved in the post-transcriptional regulation of gene expression. It acts primarily by binding to complementary sequences in the 3′ untranslated regions (3′UTRs) of target mRNAs, such as FOS-like antigen 2 (FOSL2), leading to mRNA degradation or translational repression[1][3][4]. miR-597 is frequently downregulated in several human cancers, including breast cancer and colorectal cancer, where it functions as a tumor suppressor by inhibiting cell proliferation, migration, invasion, and promoting apoptosis[1][3][4]. In myelodysplastic syndromes, miR-597 is found to be upregulated and induces apoptosis by downregulating FOSL2[4]. Due to its disease associations and role in regulating malignancy-related pathways such as EMT and cell cycle progression, miR-597 (and its expression levels) may serve as a biomarker for diagnosis or prognosis in certain cancers and is considered a potential therapeutic target[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA-597 (miR-597).